Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
2011-005781-38Phase 2Completed
- Sponsor
- Amgen
- Start
- Feb 2012
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of blinatumomab in diffuse large B-cell lymphoma (DLBCL), sponsored by Amgen. Primary endpoint: Overall response rate. Started Feb 2012; status: completed.
02
Drugs
blinatumomab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2011-005781-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005781-38.